Prof. Du Juan (杜鹃) — Multiple Myeloma Targeted Therapy & CAR-T | Changzheng Hospital Shanghai
For international patients with multiple myeloma — particularly those seeking access to cutting-edge CAR-T immunotherapy or novel targeted agents — Prof. Du Juan (杜鹃) at Changzheng Hospital Shanghai represents one of China's most focused and internationally recognized specialists in this field. Over the past decade, Prof. Du has dedicated her clinical and research career to the targeted treatment and molecular mechanisms of multiple myeloma, building expertise in CAR-T cell therapy that is recognized as being at the international forefront.
Specialty Focus
- Multiple myeloma: targeted therapy, novel agent combinations, and CAR-T immunotherapy
- Molecular mechanisms of myeloma drug resistance and disease progression
- BCMA-targeted CAR-T cell therapy for relapsed/refractory myeloma
- Proteasome inhibitors, IMiDs, anti-CD38 monoclonal antibodies, and next-generation targeted agents
- Autologous stem cell transplantation (ASCT)
- Plasma cell disorders: smoldering myeloma, AL amyloidosis
Academic & Clinical Titles
- Chief Physician & Professor, Department of Hematology, Changzheng Hospital, Naval Medical University Shanghai
- Vice-Chair, Hematology Branch, Shanghai Medical Association
- Internationally recognized expertise in CAR-T immunotherapy for multiple myeloma
- Principal investigator in multiple clinical trials in myeloma targeted therapy and CAR-T
A Decade of Focused Myeloma Expertise
Multiple myeloma is a disease where depth of subspecialty focus translates directly into better patient outcomes. Prof. Du Juan has spent the past decade concentrating her clinical and research efforts almost exclusively on myeloma — specifically on the molecular mechanisms that drive disease progression and drug resistance, and on the development of targeted therapies and cellular immunotherapies that can overcome these mechanisms.
This focused approach means that Prof. Du's understanding of myeloma biology goes beyond the clinical surface. When a patient's disease becomes refractory to standard agents, Prof. Du's research background in resistance mechanisms informs her clinical decision-making in ways that a generalist hematologist cannot replicate. For patients with relapsed/refractory myeloma who have exhausted standard options, this depth of molecular understanding is particularly valuable.
CAR-T Therapy: International-Level Expertise
Prof. Du Juan's CAR-T expertise is one of her most distinctive clinical assets. China has been a global leader in the development and clinical application of BCMA-targeted CAR-T therapy for multiple myeloma — a field where Chinese researchers and clinicians have made contributions that are recognized internationally. Prof. Du's work in this area places her among the leading CAR-T practitioners in China.
What is BCMA CAR-T therapy? B-cell maturation antigen (BCMA) is a protein highly expressed on myeloma cells and is the primary target for the most advanced myeloma CAR-T products. CAR-T therapy involves engineering a patient's own T-cells to express a chimeric antigen receptor that recognizes BCMA, then expanding these cells and reinfusing them to mount a powerful anti-myeloma immune response. In clinical trials, BCMA CAR-T therapy has produced overall response rates of 70–98% in heavily pretreated patients, including complete responses in patients who had failed multiple prior lines of therapy.
China has approved multiple BCMA CAR-T products and has accumulated one of the world's largest clinical experiences with this modality. For international patients who cannot access CAR-T therapy in their home country — due to cost, availability, or eligibility criteria — Shanghai's leading myeloma centers, including Changzheng Hospital, offer a meaningful alternative.
Changzheng Hospital: A Major Military Medical University Center
Changzheng Hospital is affiliated with Naval Medical University (formerly Second Military Medical University) — one of China's premier military medical institutions with a strong tradition of clinical excellence and research. The hospital's hematology department benefits from the institutional infrastructure of a major academic medical center, including access to advanced laboratory diagnostics, clinical trial programs, and multidisciplinary subspecialty support.
For myeloma patients, Changzheng's comprehensive support services — including nephrology for renal impairment management, cardiology for cardiac amyloidosis, and infectious disease for infection prophylaxis during immunosuppressive therapy — are important complements to Prof. Du's hematology expertise.
Molecular Research Informing Clinical Practice
Prof. Du Juan's research into the molecular mechanisms of myeloma has practical clinical implications for her patients. Understanding why myeloma cells become resistant to bortezomib, lenalidomide, or daratumumab — and identifying the molecular pathways that drive this resistance — informs the selection of subsequent therapies and the design of combination regimens that can overcome resistance.
For patients who have progressed on multiple lines of therapy and whose oncologists are uncertain about next steps, Prof. Du's research background provides a framework for identifying rational treatment options based on the biology of the individual patient's disease, rather than simply moving through a standard treatment algorithm.
Who Should Consider Consulting Prof. Du Juan
- Relapsed or refractory myeloma patients who have progressed on proteasome inhibitors, IMiDs, and/or anti-CD38 antibodies
- Triple-class refractory patients being evaluated for BCMA CAR-T therapy eligibility
- Patients with myeloma who want access to clinical trials in novel targeted agents or CAR-T combinations
- Newly diagnosed high-risk myeloma patients seeking expert second opinion on induction and consolidation strategy
- Patients with myeloma-related AL amyloidosis or renal impairment requiring integrated management
- Patients whose oncologists have identified drug resistance and are uncertain about next-line options
How CMCS Connects You with Prof. Du Juan
China Medical Concierge Shanghai (CMCS) facilitates access to Prof. Du Juan for international patients with multiple myeloma. Our team manages the full coordination process — from remote case review and medical record translation to appointment scheduling, interpretation, and in-hospital support throughout the consultation and treatment process.
To begin, patients or their families are encouraged to share available medical records including bone marrow biopsy and cytogenetics reports (FISH panel for del17p, t(4;14), t(14;16), gain 1q), M-protein quantification (SPEP, UPEP, serum free light chains), imaging studies (whole-body low-dose CT or PET-CT), renal and cardiac function assessments, and prior treatment summaries. Prof. Du's team can conduct an initial remote assessment — including CAR-T eligibility evaluation — before any travel to Shanghai is required.
CMCS provides end-to-end support including:
- Medical record translation (English, Arabic, French, and other languages)
- Remote pre-consultation case review and CAR-T eligibility assessment
- Appointment coordination with Prof. Du Juan's clinic at Changzheng Hospital
- On-site interpretation during consultations and procedures
- Clinical trial identification and enrollment support
- Post-consultation summary and follow-up support
Contact CMCS to Connect with Prof. Du Juan
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician.
0 comentarios